Novartis Ag

The General Hospital Corporation

The General Hospital Corporation D/b/a Massachusetts General Hospital

Huaixiang Hao

Jun Liu

Matthew J LaMarche

Shailaja Kasibhatla

Lloyd B Klickstein

Fang Li

Feng Cong

Xizhong Huang

Xiaomo Jiang

Ann Taylor

Ying-Nan Pan Chen

Jeffrey Engelman

Hui-Qin Wang

Yang Xie

Rou-fun Kwong

Nicholas Ng

Matthew J Lamarche

Chen Liu

Leila Dardaei Alghalandis

Morvarid Mohseni

Angela Tam

Hsin-I Hsieh

Rou-Fun Kwong

Jeffrey Adam Engelman

The present invention relates to a pharmaceutical combination comprising TNO155 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

Pharmaceutical combination comprising TNO155 and ribociclib

A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor described herein, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.

Combination therapy

The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of &#x3b2;-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

Antibodies and methods for WNT pathway-related diseases

Growing community of inventors

Malden, MA, United States of America

Huaixiang Hao